LINC01498: A Potential Drug Target and Biomarker (G102723562)

Target Name: LINC01498

NCBI ID: G102723562

LINC01498

Other Name(s): Long intergenic non-protein coding RNA 1498 | long intergenic non-protein coding RNA 1498

LINC01498: A Potential Drug Target and Biomarker

LINC01498 is a non-protein coding RNA (ncRNA) molecule that has been identified as a potential drug target and biomarker. It is a long intergenic non-protein coding RNA (lncRNA), which means it is not a protein but rather a RNA molecule that is derived from the cytosm. LINC01498 has been found to be highly expressed in various tissues and has been associated with various diseases, including cancer. Therefore, it is of great interest to investigate its potential as a drug target and biomarker.

Drug Target Potential

LINC01498 has been shown to be involved in various cellular processes, including cell growth, survival, and angiogenesis. It has been shown to play a role in the regulation of cell adhesion, which is important for various cellular processes, including tissue repair and regeneration. LINC01498 has also been shown to be involved in the regulation of cell cycle progression, which is important for the development and progression of cancer.

Furthermore, LINC01498 has been shown to be involved in the regulation of cellular signaling pathways, including the NF-kappa pathway. NF-kappa is a well-known signaling pathway that is involved in various cellular processes, including cell growth, differentiation, and survival. LINC01498 has been shown to play a role in the regulation of NF-kappa signaling by negative modulation of its expression.

Biomarker Potential

LINC01498 has also been shown to be involved in the regulation of various biological processes, including cell death, cell signaling, and inflammation. Therefore, it has great potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

LINC01498 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. During apoptosis, LINC01498 has been shown to play a role in the regulation of various cellular signaling pathways, including the Bcl-2 pathway. Bcl-2 is a well-known gene that has been shown to play a role in the regulation of apoptosis, and LINC01498 has been shown to interact with Bcl-2 to regulate its expression.

Furthermore, LINC01498 has been shown to be involved in the regulation of cellular signaling pathways related to inflammation. LINC01498 has been shown to play a role in the regulation of the NF-kappa-B pathway, which is involved in the regulation of inflammation.

Conclusion

In conclusion, LINC01498 is a long intergenic non-protein coding RNA molecule that has been identified as a potential drug target and biomarker. Its potential as a drug target is based on its involvement in various cellular processes, including cell growth, survival, and angiogenesis, as well as its involvement in the regulation of cellular signaling pathways, including NF-kappa and NF-kappa-B. Its potential as a biomarker is based on its involvement in the regulation of various biological processes, including cell apoptosis and inflammation. Further research is needed to fully understand the potential of LINC01498 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1498

The "LINC01498 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01498 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets